Neekesh V. Dharia

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Supplementary Figure S4 from Targeting the Sodium–Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia

  2026-06-17

• Supplementary Table S4 from Targeting the Sodium–Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia

  2026-06-17

• Supplementary Table S3 from Targeting the Sodium–Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia

  2026-06-17

• Supplementary Figure S6 from Targeting the Sodium–Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia

  2026-06-17

• Supplementary Table S2 from Targeting the Sodium–Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia

  2026-06-17

• Supplementary Figure S2 from Targeting the Sodium–Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia

  2026-06-17

• Supplementary Figure S5 from Targeting the Sodium–Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia

  2026-06-17

• Supplementary Table S1 from Targeting the Sodium–Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia

  2026-06-17

• Supplementary Figure S9 from Targeting the Sodium–Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia

  2026-06-17

• Supplementary Figure S3 from Targeting the Sodium–Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia

  2026-06-17

• Supplementary Figure S10 from Targeting the Sodium–Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia

  2026-06-17

• Supplementary Figure S7 from Targeting the Sodium–Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia

  2026-06-17

• Supplementary Figure S8 from Targeting the Sodium–Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia

  2026-06-17

• Supplementary Figure S1 from Targeting the Sodium–Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia

  2026-06-17

• Abstract 3500: Synergistic targeting of EP300/CBP and EYA co-activators collapses the rhabdomyosarcoma core regulatory circuit

  Cancer Research · 2026-04-03

• Supplementary Figures from An <i>In Vivo</i> CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML

  2025-12-09

• Supplementary Tables from An <i>In Vivo</i> CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML

  2025-12-09

• Supplementary Data from An <i>In Vivo</i> CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML

  2025-12-09

• Single-Agent Divarasib in Patients With <i>KRAS G12C</i> –Positive Non–Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study

  Journal of Clinical Oncology · 2025-07-09 · 21 citations

• Abstract 2514: Refining oncology dose selection: A framework for tailored dose optimization in the era of targeted and immunotherapies

  Cancer Research · 2025-04-21